ClinicalTrials.Veeva

Menu
S

START | Barcelona

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tavapadon
Emricasan
Ribavirin
ARGX-113
Anecortave Acetate
Telaprevir
CVL-865
Peginterferon
TX000045
PPSGG

Parent organization

This site is a part of START

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 14 total trials

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045...

Enrolling
Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension
Drug: TX000045- Dose A
Drug: TX000045- Dose B

The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Park...

Active, not recruiting
Parkinson Disease
Drug: Tavapadon

Trial sponsors

Cerevel Therapeutics logo
Alcon logo
D
H
M
P
Vertex Pharmaceuticals logo
argenx logo
S
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems